Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19

IntroductionThe emergence of the Omicron SARS-CoV-2 variant of concern in late November 2021 presaged yet another stage of the COVID-19 pandemic. Paxlovid, a co-packaged dosage form of two antiviral drugs (nirmatrelvir and ritonavir) developed by Pfizer, received its first FDA Emergency Use Authorization (EUA) and conditional marketing by European Medical Agency in patients at high risk of developing severe COVID-19.Areas coveredWe reviewed the timeline of the drug nirmatrelvir from its discovery to authorization by FDA. After 1 year of its authorization, numerous studies and reports on paxlovid's use and post-use consequences are available. This review summarizes the complete journey of paxlovid from its development, preclinical studies, clinical trials, regulatory approvals, ongoing clinical trials, and safety measures, followed by discussions on recent updates on drug-drug interactions, adverse effects, and relapse of COVID-19.Expert opinionPaxlovid, a new oral antiviral therapy for COVID-19, has shown promising results in clinical trials and has the potential to be effective against the pandemic, particularly for individuals at high risk of severe illness. Comorbidity usage and pharmacovigilance will play a significant stake in the future of paxlovid development. Second-generation M-pro inhibitors play an important role in the upcoming problems associated with COVID-19.

Automated summary

The emergence of the Omicron variant in late November 2021 marked another stage in the COVID-19 pandemic. Pfizer's antiviral drug Paxlovid, a combination of nirmatrelvir and ritonavir, received FDA Emergency Use Authorization and conditional marketing by the European Medical Agency for high-risk COVID-19 patients.